3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
2
Status
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
NET
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Sorafenib
79
pembrolizumab
37
Bevacizumab
36
Nivolumab
33
lenvatinib
30
atezolizumab
24
durvalumab
17
Oxaliplatin
12
Ipilimumab
12
regorafenib
9
Capecitabine
9
tremelimumab
8
Injections
8
Doxorubicin
8
tislelizumab
7
sintilimab
7
Fluorouracil
7
cabozantinib
6
budigalimab
6
brivanib
6
Ramucirumab
6
toripalimab
5
Gemcitabine
5
Everolimus
5
Cyclophosphamide
5
ADI PEG20
5
fludarabine
4
Sunitinib
4
Leucovorin
4
E-7386
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Hepatocellular
×
gadoterate meglumine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled
NCT01806740
2019-08-08
DCE-MRI
Guerbet
Phase 4
Terminated
37 enrolled
12 charts